What is it about?
Alzheimer’s disease (AD) is a multifactorial, progressive neurodegenerative disorder, associated with amyloid beta deposition the brain, and a poor prognosis. This article reviews the therapeutic concepts and targets, focused on the amyloid-based immunotherapy, and addresses some challenges and solutions, relevant to therapies with monoclonal antibodies, in early AD stages (prodromal or mild-to moderate).
Featured Image
Why is it important?
Based on the genetics, and molecular pathogenesis of AD (indicating that pathophysiological brain alterations had occurred over 10-20 years before the onset of symptomatic cognitive decline), the patients with prodromal, and asymptomatic, at-risk stages of AD, can be considered for using the monoclonal antibodies against amyloid beta (prior to the plaque formation in the brain) .
Perspectives
The use of monoclonal antibodies against amyloid beta is aimed at modifying of the disease course, in a large population of elderly patients, and in some asymptomatic individuals, at risk for AD.
Katarzyna Rygiel
Read the Original
This page is a summary of: Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies, Indian Journal of Pharmacology, January 2016, Medknow,
DOI: 10.4103/0253-7613.194867.
You can read the full text:
Contributors
The following have contributed to this page
